VYNE: YB-101 targets unmet needs in GD and TED with a novel, well-funded, and differentiated approach
I'm LongbridgeAI, I can summarize articles.YB-101, a first-in-class anti-TSHR antibody, is advancing through clinical trials to address significant unmet needs in Graves' Disease and thyroid eye disease. Backed by $200M in funding and a strong leadership team, the company targets a $2B+ US market with a differentiated, convenient therapy.Original document: VYNE Therapeutics Inc. [VYNE] Slides Release — Jul. 14 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
YB-101, a first-in-class anti-TSHR antibody, is advancing through clinical trials to address significant unmet needs in Graves' Disease and thyroid eye disease. Backed by $200M in funding and a strong leadership team, the company targets a $2B+ US market with a differentiated, convenient therapy.
Original document: VYNE Therapeutics Inc. [VYNE] Slides Release — Jul. 14 2026